PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 EPAS ID: PAT6774181 Stylesheet Version v1.2

SUBMISSION TYPE: NEW ASSIGNMENT NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
DAVID GOLDSTEIN	06/17/2016
TIMOTHY D. OWENS	06/16/2016

RECEIVING PARTY DATA

Name:	PRINCIPIA BIOPHARMA INC.	
Street Address:	400 EAST JAMIE COURT	
Internal Address:	SUITE 302	
City:	SOUTH SAN FRANCISCO	
State/Country:	CALIFORNIA	
Postal Code:	94080	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16523979

CORRESPONDENCE DATA

Fax Number: (617)812-1277

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6174304740

Email: DOCKETING@MCNEILLBAUR.COM

MCNEILL BAUR PLLC **Correspondent Name:**

Address Line 1: 125 CAMBRIDGE PARK DRIVE

Address Line 2: **SUITE 301**

Address Line 4: CAMBRIDGE, MASSACHUSETTS 02140

ATTORNEY DOCKET NUMBER: 01183-0128-01US **NAME OF SUBMITTER:** CHRISTINE DONAHUE SIGNATURE: /christine donahue/ **DATE SIGNED:** 06/22/2021

Total Attachments: 2

source=Provisional Assignment-executed#page1.tif source=Provisional Assignment-executed#page2.tif

PATENT REEL: 056616 FRAME: 0972 506727365

ASSIGNMENT

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

TYROSINE KINASE INHIBITORS

as disclosed and claimed in United States Application No. 62/183,969, filed June 24, 2015 (Confirmation No. 8767) and/or United States Application No. 62/271,715, filed December 28, 2015 (Confirmation No. 1026) and;

WHEREAS, **Principia Biopharma Inc.**, a corporation of Delaware, whose post office address is 400 East Jamie Court, Suite 302, South San Francisco, CA 94080 (hereinafter referred to as Assignee), desires to own the entire right, title, and interest in and to this invention in all countries throughout the world, any and all application(s) for patents in any country, including any international applications filed under the Patent Cooperation Treaty (PCT) or other multinational agreement and any national stage entry applications in any country based thereon, and any and all Letters Patent to be issued upon such filed application(s) in any country;

NOW THEREFORE, be it known that, for good and valuable consideration, the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, interest in and to this invention in all countries throughout the world, application(s) for patents in any country, including any provisional applications, non-provisional applications, and continuation, divisional, or continuation-in-part applications that disclose the invention, any international applications filed under the Patent Cooperation Treaty (PCT) or other multinational agreement and any national stage entry applications in any country based thereon, and any and all Letters Patent, utility model patents, and certificates of invention to be issued upon such filed application(s) in any country and any extensions, restorations, renewals, or reissues thereof;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

1 601dstein 217, 2016

ASSIGNOR (Inventor) 1

Signature

Print Name

Execution Date

PATENT REEL: 056616 FRAME: 0973

ASSIGNOR (Inventor) 2

Signature

Imothy U. Owens

Print Name

Execution Date

Assignee Name:

Principia Biopharma Inc.

Signature:

Printed Name:

Corporate Title:

Date:

6/17/16

PATENT REEL: 056616 FRAME: 0974

RECORDED: 06/22/2021